Why the study?
Established SCD risk models have suboptimal discriminative power in hypertrophic cardiomyopathy, prompting debate regarding the optimal risk stratification strategy.
Does an LGE amount >5% of LV mass on CMR predict sudden cardiac death in patients with hypertrophic cardiomyopathy?
Does an LGE amount >5% of LV mass on CMR predict sudden cardiac death in patients with hypertrophic cardiomyopathy?
An LGE extent >5% of LV mass on CMR identifies hypertrophic cardiomyopathy patients at high long-term risk for sudden cardiac death, suggesting its utility in guiding primary prevention ICD placement beyond traditional risk scores.
Answers are grounded in this paper and cite their sources.
Supports LGE quantification for long-term SCD risk stratification in HCM; leaves open impact on ICD decisions pending prospective data.
AIMS: Sudden cardiac death (SCD) is an appalling complication of hypertrophic cardiomyopathy (HCM). There is an ongoing discussion about the optimal SCD risk stratification strategy since established SCD risk models have suboptimal discriminative power. The aim of this study was to evaluate the prognostic value of late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) for SCD risk stratification compared to the European Society of Cardiology (ESC) SCD risk score and traditional risk factors in an >10-year follow-up. METHODS AND RESULTS: Two hundred and twenty consecutive patients with HCM and LGE-CMR were enrolled. Follow-up data were available in 203 patients (median age 58 years, 61% male) after a median follow-up period of 10.4 years. LGE was present in 70% of patients with a median LGE amount of 1.6%, the median ESC 5-year SCD risk score was 1.84. In the overall cohort, SCD rates were 2.3% at 5 years, 4.8% at 10 years, and 15.7% at 15 years, independent from established risk models. An LGE amount of >5% left ventricular (LV) mass portends the highest risk for SCD with SCD prevalences of 5.5% at 5 years, 13.0% at 10 years, and 33.3% at 15 years. Conversely, patients with no or ≤5% LGE of LV mass have favourable prognosis. CONCLUSIONS: LGE-CMR in HCM patients allows effective 10-year SCD risk stratification beyond established risk factors. LGE amount might be added to established risk models to improve its discriminatory power. Specifically, patients with >5% LGE should be carefully monitored and might be adequate candidates for primary prevention implantable cardioverter-defibrillator during the clinical long-term course.
No takes yet. Share an insight, caveat, or question.
Greulich et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: